Article
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Annals of internal medicine - 3 Dec 2013
Liu Chen-Hua, Huang Chung-Feng, Liu Chun-Jen, Dai Chia-Yen, Liang Cheng-Chao, Huang Jee-Fu, Hung Peir-Haur, Tsai Hung-Bin, Tsai Meng-Kun, Chen Shih-I, Lin Jou-Wei, Yang Sheng-Shun, Su Tung-Hung, Yang Hung-Chih, Chen Pei-Jer, Chen Ding-Shinn, Chuang Wan-Long, Yu Ming-Lung, Kao Jia-Horng
Abstract excerpt
BACKGROUND: Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis. OBJECTIVE: To compare the efficacy and safety of combination therapy with pegylated interferon plus low-dose ribavirin and pegylated interferon monotherapy for treatment-naive patients with HCV-1 receiving hemodialysis. DESIGN: Open-label,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.